Empowering clinicians with AI medical technologies that solve real challenges.

About Us

Keya Medical is an international medical technology company developing deep learning-based medical devices for disease diagnosis and treatment. The company is committed to creating solutions that deliver clinical value at all stages in the patient care process, covering specialties including cardiology, neurology, pulmonology, pathology, and surgery.

Keya Medical has four centers of excellence in Beijing, Shanghai, Shenzhen, and Seattle. To learn more about Keya Medical, follow us on LinkedInTwitter, and Facebook.

Certifications of CT FFR Analysis – DEEPVESSEL FFR

NMPA

January 2020

CE

August 2018

FDA

April 2022

HSA

July 2023

Comprehensive R&D Pipeline Solution Suites

Keya Medical Comprehensive Solutions

Keya Medical is developing a comprehensive R&D pipeline to deliver clinical value throughout the patient care process. The product candidates in our pipeline will be designed for use in early screening, diagnosis, treatment, and post-treatment followup.

By the Numbers

Employees

Collaboration Partners

Registered Patents

Milestones

\
2016

Keya Medical is founded

\
2017

Keya Medical establishes the first AI diagnostic laboratory

\
2018

DeepVessel FFR enters the CFDA Special Approval Channel for Innovative Medical Devices

Keya Medical receives ISO 13485 certification

DeepVessel FFR receives CE Mark

\
2019

Keya Medical is selected to the Top 100 Medical Companies of the Future list by VCBeat Research

\
2020

DeepVessel FFR becomes the first Class-III AI medical device approved for clinical use by the Chinese National Medical Products Administration

$15 million in strategic funding

$20 million in Series B+ funding

$30 million in Series C funding

$46 million in Series D funding

\
2021

DeepVessel FFR demonstrates an accuracy of 92% in a single-center retrospective study conducted by researchers at Fuwai Hospital

\
2022

ADAPT clinical trial is completed

DeepVessel FFR received FDA clearance

\
2023

The TARGET Randomized Trial presented at Late-breaking science at ACC 2023

\
2024

DeepVessel FFR joins Calantic (Bayer) AI platrform

\
2023

DeepVessel FFR receives Singapore HSA certification